Clinical Trials Browser

NSCLC × lenvatinib × Clear all

NCT05078931 2025-07-30

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Phase 2 Active not recruiting

NSCLC